This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Leaders of TheStreet's Drug Approval Contest

Stocks in this article: SRPT AVEO DCTH ZIOP APPA UTHR

This story has been corrected to include Dawid, another contestant among the leaders who was excluded by mistake.

BOSTON ( TheStreet) -- Back in March, I posted a challenge for readers: Predict the outcome of 12 regulatory events -- plus one clinical trial result. We're two months into TheStreet's Drug Approval Contest, and while I can't crown official winners just yet, it's close enough that an update is in order.

The negative votes at last Thursday's FDA advisory panels for both Aveo Oncology's (AVEO) tivozanib and Delcath Systems (DCTH) Melblez created big swings in the standings but also cemented the leaders in place.

With 11 events already decided, there is a group of four contestants tied for first place with impressive 10-1 records. They are:

Stanley D'Andrea (Twitter @stanleydandrea): His only mis-step so far has been the Delcath FDA panel decision. He predicted a positive vote, which was obviously the wrong way to go.

BBBtech (Twitter @biotechtoreador): Perfect picks except for calling the approval of A.P. Pharma's (APPA) APF530, which FDA rejected.

Prpcm: Also perfect except for A.P. Pharma.

Ryan H. (Twitter @HaggertyRyan): His only blemish was Ziopharm Oncology (ZIOP). predicting positive results from the palifosfamide phase III trial. As we all know, the study failed.

Pretty awesome job, guys. Congratulations.

Sitting tight behind these distinguished drug-approval forecasters is a group of six contestants with 9-2 records. Not too shabby at all. They are:

Zzlangerhans (Twitter @zzlangerhans): Missed A.P. Pharma and Aveo.

Steve Sabba: Missed Titan Pharma (TTNP) and Ziopharm.

Jeffrey the Great (Twitter @jtg_investor): Missed A.P. Pharma and Ziopharm.

Brice Foose (Twitter @PharmDFoose): Missed A.P. Pharma and Aveo.

Dawid: Missed A.P. Pharma and Ziopharm.

Lastly, yours truly, Adam Feuerstein (Twitter @adamfeuerstein). I screwed up on A.P. Pharma and Ziopharm.

Take a bow, guys.

Eleven of 13 events have been decided, leaving only the FDA approval decision for Delcath's Melblez and Sarepta Therapeutics' (SRPT) eteplitsen accelerated approval filing unresolved. Given the 0-16 vote against Meblez Thursday, it's safe to assume FDA will follow through with a formal rejection on June 14. All the front-runners listed above predicted a Delcath rejection except Stanley D'Andrea. That mistake will knock him from the group tied for first place.

Sorry about that, Stan.

So, that leaves Sarepta as the last and decisive event. This is where the contest gets fun:

If Sarepta files for accelerated approval (decision expected later this quarter), Prpcm and Ryan H. win the contest, each with an astounding record of 12-1.

If Sarepta does not file, the contest winner will be BBBtech.

Among the nine top contestants discussed above, six predict a Sarepta accelerated approval filing for eteplirsen; three believe no such filing will take place.

Lastly, I want to commend everyone who participated in the contest. The "wisdom of the crowd" effect this time around was really quite remarkable. As a group, the 113 participants in the contest are a combined 8-3, getting only A.P. Pharma, United Therapeutics (UTHR) and Ziopharm incorrect. Add in the inevitable FDA rejection of Delcath's Melblez and the crowd is 9-3.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,059.34 +5.63 0.03%
S&P 500 2,093.14 +4.37 0.21%
NASDAQ 4,811.9050 +5.0460 0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs